256 related articles for article (PubMed ID: 12393839)
1. Bacterial infectious disease control by vaccine development.
Curtiss R
J Clin Invest; 2002 Oct; 110(8):1061-6. PubMed ID: 12393839
[No Abstract] [Full Text] [Related]
2. [The outlook for developing recombinant vaccines based on mycobacteria].
Lazarenko VN; Makhlaĭ AA; Khomenko AG
Vestn Ross Akad Med Nauk; 1993; (2):37-9. PubMed ID: 7688618
[TBL] [Abstract][Full Text] [Related]
3. Can a 'flawless' live vector vaccine strain be engineered?
Galen JE; Levine MM
Trends Microbiol; 2001 Aug; 9(8):372-6. PubMed ID: 11514219
[TBL] [Abstract][Full Text] [Related]
4. New ways to identify novel bacterial antigens for vaccine development.
Movahedi AR; Hampson DJ
Vet Microbiol; 2008 Sep; 131(1-2):1-13. PubMed ID: 18372122
[TBL] [Abstract][Full Text] [Related]
5. An overview of vaccine vectors.
Dorner F
Dev Biol Stand; 1995; 84():23-32. PubMed ID: 7796959
[No Abstract] [Full Text] [Related]
6. Technologies for the design, discovery, formulation and administration of vaccines.
Ellis RW
Vaccine; 2001 Mar; 19(17-19):2681-7. PubMed ID: 11257409
[TBL] [Abstract][Full Text] [Related]
7. Salmonellae as oral vaccine carriers.
Schödel F; Curtiss R
Dev Biol Stand; 1995; 84():245-53. PubMed ID: 7796961
[No Abstract] [Full Text] [Related]
8. Hybrid vaccines using Escherichia coli as an antigen carrier.
Hale TL
Res Microbiol; 1990; 141(7-8):913-9. PubMed ID: 2101482
[No Abstract] [Full Text] [Related]
9. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus.
Sutter G; Moss B
Dev Biol Stand; 1995; 84():195-200. PubMed ID: 7796954
[No Abstract] [Full Text] [Related]
10. Alternative methods of attenuating Salmonella species for potential vaccine use.
Wilson DR; Chatfield S; Betts J; Griffiths A; Leung KY; Dougan G; Finlay BB
Res Microbiol; 1990; 141(7-8):827-30. PubMed ID: 1966254
[TBL] [Abstract][Full Text] [Related]
11. Vaccination today and tomorrow.
Brown F
Biosci Rep; 1995 Dec; 15(6):493-502. PubMed ID: 9156579
[TBL] [Abstract][Full Text] [Related]
12. [Trends in the studies of the preparations of active and passive immunization. Bacterial vaccines].
Gałazka A
Przegl Epidemiol; 1988; 42(4):317-31. PubMed ID: 3247475
[No Abstract] [Full Text] [Related]
13. Naturally occurring Clostridium perfringens nontoxic alpha-toxin variant as a potential vaccine candidate against alpha-toxin-associated diseases.
Schoepe H; Pache C; Neubauer A; Potschka H; Schlapp T; Wieler LH; Baljer G
Infect Immun; 2001 Nov; 69(11):7194-6. PubMed ID: 11598102
[TBL] [Abstract][Full Text] [Related]
14. Salmonella-based vaccines for infectious diseases.
Kwon YM; Cox MM; Calhoun LN
Expert Rev Vaccines; 2007 Apr; 6(2):147-52. PubMed ID: 17408365
[TBL] [Abstract][Full Text] [Related]
15. Construction of an invertible DNA segment for improved antigen expression by a hybrid Salmonella vaccine strain.
Yan ZX; Reuss F; Meyer TF
Res Microbiol; 1990; 141(7-8):1003-4. PubMed ID: 2101464
[No Abstract] [Full Text] [Related]
16. From vaccine research to manufacture: a guide for the researcher.
Allison N; Tranter HS
Methods Mol Med; 2003; 87():391-408. PubMed ID: 12958469
[No Abstract] [Full Text] [Related]
17. Recent advances in the development of live, attenuated bacterial vectors.
Roland KL; Tinge SA; Killeen KP; Kochi SK
Curr Opin Mol Ther; 2005 Feb; 7(1):62-72. PubMed ID: 15732531
[TBL] [Abstract][Full Text] [Related]
18. Rational design of gene-based vaccines.
Barouch DH
J Pathol; 2006 Jan; 208(2):283-9. PubMed ID: 16362986
[TBL] [Abstract][Full Text] [Related]
19. Recent advances with recombinant bacterial vaccine vectors.
Shata MT; Stevceva L; Agwale S; Lewis GK; Hone DM
Mol Med Today; 2000 Feb; 6(2):66-71. PubMed ID: 10652479
[TBL] [Abstract][Full Text] [Related]
20. A stable plasmid system for heterologous antigen expression in attenuated Vibrio anguillarum.
Xiao Y; Liu Q; Chen H; Zhang Y
Vaccine; 2011 Sep; 29(40):6986-93. PubMed ID: 21791231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
